Evidence map›Paper›PMID 26133519›Full record

Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction.

N Martínez-Lago, M Vieito-Villar, Y Vidal-Insua, M E Padin-Iruegas, F Vazquez-Rivera, S Candamio-Folgar, R Lopez-Lopez

Open access · greenAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

N Martínez-LagoMedical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Travesía de a Choupana S/N Santiago de Compostela, 15706, La Coruña, Spain. nievesmartinezlago@gmail.com.
M Vieito-VillarMedical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Travesía de a Choupana S/N Santiago de Compostela, 15706, La Coruña, Spain.
Y Vidal-InsuaMedical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Travesía de a Choupana S/N Santiago de Compostela, 15706, La Coruña, Spain.
M E Padin-IruegasDepartment of Functional Biology and Health Sciences, Human Anatomy and Embryology Section, University of Vigo, Vigo, Pontevedra, Spain.
F Vazquez-RiveraMedical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Travesía de a Choupana S/N Santiago de Compostela, 15706, La Coruña, Spain.
S Candamio-FolgarMedical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Travesía de a Choupana S/N Santiago de Compostela, 15706, La Coruña, Spain.
R Lopez-LopezMedical Oncology Department, Hospital Clínico Universitario, Santiago de Compostela, Travesía de a Choupana S/N Santiago de Compostela, 15706, La Coruña, Spain.
Complejo Hospitalario Universitario de Santiago · ESUniversidade de Vigo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity. We explored the efficacy and toxicity of a modified 5-fluorouracil continuous infusion scheme.

methodsWe conducted an observational retrospective study in our centre. Gastric/gastroesophageal junction adenocarcinoma patients were treated with a schedule consisting in four infusions of bolus 5-fluorouracil 400 mg/m(2) iv with leucovorin 200 mg/m(2) iv and 1200 mg/m(2) in 46-hour infusion of 5-fluorouracil (D'Gramont scheme), followed by concomitant radiochemotherapy (45 Gy in 25 fractions of 1.8 Gy) with 5-fluorouracil continuously infusion 225 mg/m(2)/day and four additional infusions of chemotherapy one month after complete radiochemotherapy.

resultsBetween January 2007 and December 2013, 55 patients received a mean of 3.16 bi-weekly adjuvant infusions followed by 4.6 weeks of continuous treatment concurrent with radiotherapy and 3.72 bi-weekly infusions after radiotherapy treatment. During adjuvant treatment, grade III toxicity was mostly haematologic, while gastrointestinal and cutaneous toxicity was predominant during concurrent treatment. There were no grade IV- or treatment-related deaths during this study. Disease-free survival (DFS) was 79.2 months (56.3-102.1 months), and the 3-year survival rates were 52.7 %.

conclusionsThis 5-fluorouracil infusional scheme has an excellent tolerability profile and favourable efficacy results.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyChemotherapy, AdjuvantDisease-Free SurvivalEsophagogastric JunctionFemaleFluorouracilHumansInfusions, IntravenousKaplan-Meier EstimateLeucovorinAntineoplastic AgentsFluorouracilLeucovorin5-Fluorouracil infusionalGastric cancerToxicity

Identifiers

PMID26133519
OpenAlexW750120495

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.